Moderna Inc
$ 53.72
-1.76%
17 Apr - close price
- Market Cap 21,304,646,000 USD
- Current Price $ 53.72
- High / Low $ 56.06 / 52.95
- Stock P/E N/A
- Book Value 21.95
- EPS -7.26
- Next Earning Report 2026-05-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.29 %
- 52 Week High 59.55
- 52 Week Low 22.28
About
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$46.10
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-06 | 2025-08-01 | 2025-04-30 | 2025-02-20 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -2.11 | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 | 0.19 |
| Estimated EPS | -2.62 | -2.05 | -2.98 | -3.03 | -2.7599 | -1.9 | -3.38 | -3.58 | -0.97 | -1.93 | -4.04 | -1.77 |
| Surprise | 0.51 | 1.54 | 0.85 | 0.51 | -0.1501 | 1.93 | 0.05 | 0.51 | 1.52 | -7.6 | 0.42 | 1.96 |
| Surprise Percentage | 19.4656% | 75.122% | 28.5235% | 16.8317% | -5.4386% | 101.5789% | 1.4793% | 14.2458% | 156.701% | -393.7824% | 10.396% | 110.7345% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-04-19 18:48:30
Pfizer's Comirnaty vaccine sales have drastically fallen since the pandemic's peak, prompting a strategic shift towards new markets and therapies. The company is diversifying into oncology with the acquisition of Seagen and investing in other vaccines like RSV, aiming for over 20 blockbuster drugs by 2030 to reduce reliance on any single product. While challenges like vaccine hesitancy and variant emergence persist, analysts remain cautiously optimistic about Pfizer's long-term potential due to its pipeline and cash flow.
2026-04-19 12:40:50
BioNTech is transforming into an oncology-focused company, using its €17 billion cash reserves to fund 15 Phase 3 oncology trials and targeting over €2 billion in revenue by 2026. This strategic shift comes as co-founders prepare to exit and COVID-19 vaccine revenues decline. While the company faces short-term financial pressures, including an expected loss in Q1, shareholder sentiment remains cautiously optimistic as it pushes for regulatory submissions and new clinical collaborations.
2026-04-19 04:49:19
The article discusses how Google's 2026 Discover Core Update significantly alters mobile financial news delivery, especially for Charles River Labs stock (US1598641074). This update prioritizes personalized, proactive content on biopharma trends and drug development, directly delivering insights to users' Google app feeds without requiring a search. For investors, this means quicker access to critical market information, enhancing their ability to track the dynamic biopharma services sector.
2026-04-18 11:40:08
Sanofi announced that its protein-based non-mRNA COVID-19 vaccine, Nuvaxovid, demonstrated statistically significant lower systemic reactogenicity compared to Moderna's mRNA vaccine, mNEXSPIKE, in the COMPARE study. The study showed Nuvaxovid recipients experienced less severe and shorter-duration side effects, with significantly fewer severe systemic and local symptoms. This suggests Nuvaxovid offers better tolerability, impacting fewer individuals and causing less disruption to daily activities.
2026-04-18 11:07:09
Biogen has agreed to acquire Apellis Pharmaceuticals for US$5.6 billion, a move that significantly broadens Biogen's therapeutic reach, particularly in neurology and rare diseases. This acquisition adds approved products and late-stage candidates to Biogen's portfolio, aligning with its strategy to leverage external science for both immediate product mix and long-term pipeline development. Investors will be focused on how Biogen integrates Apellis, the financial implications of the deal, and its impact on the company's existing profitability goals and growth narrative.
2026-04-18 06:40:09
Rocket Pharmaceuticals (NASDAQ:RCKT) has received a consensus "Hold" rating from eighteen brokerages, with an average 12-month price target of $13.86, significantly higher than its current share price of $3.91. The company recently beat Q4 EPS estimates but remains unprofitable, while insider selling by the CEO and General Counsel has been noted. Hedge funds and institutional investors hold a substantial portion of the stock.
